TBPH: Theravance Company Value to Net Income

Corporate emblem and logo of Theravance Biopharma Inc (TBPH)

The weighted average P/E of Theravance Biopharma (TBPH) reflects the current market valuation, where the 16.70 indicator expresses the state of the metric. This trend is driven by the focus of Theravance Biopharma on the B2B segment of respiratory and gastrointestinal therapies. Prospects rely on the development of high-precision molecules with minimal side effects. However, the growth trajectory depends on management's ability to optimize R&D costs following the asset restructuring.

TBPH Theravance Corp: Price to Earnings Ratio in the range 07/04/2022 - 10/10/2026

Comprehensive metric breakdowns and analytics for Theravance Biopharma Inc (TBPH)

- price and consensus price forecast:
- market capitalization information:
Comprehensive company analysis:Theravance - TBPH
Flagship merchandise of Theravance Biopharma, Inc.

The P/E ratio of Theravance Biopharma (TBPH) reflects the cost of a single unit of net profit, allowing the company's current market P/E to determine the extent of the asset's overvaluation relative to its actual earnings. This metric, combined with non-cyclical demand for respiratory drugs, confirms the business's high resilience to macroeconomic shocks, providing investors with a stable fundamental anchor even during periods of market volatility.

Competing companies

HLN: Company Value to Net Income|Price to Earnings Ratio KVUE (Kenvue Corp)|VRNA (Verona Pharma Inc.) - Company Value to Net Income|Price to Earnings Ratio Jyong Biotech Limited MENS|Ligand (LGND) - Market Cap to Earnings|AMRX: Price to Earnings Ratio|Perrigo - Market Price to Net Income Ratio|ALVO: P/E Multiple|Liquidia Technologies - Company Value to Net Income|GLPG (Galapagos N.V.) - P/E Multiple|Market Cap to Earnings anipharmaceuticals.com ANIP|Price to Earnings Ratio MannKind (MNKD)|AMPH (Amphastar Pharmaceuticals, Inc.) - Company Value to Net Income|Price to Earnings Ratio Pacira BioSciences, Inc. PCRX|P/E Multiple ARS Corp SPRY|AQST - Price to Earnings Ratio|scPharmaceuticals (SCPH) - Price to Earnings Ratio|TECX: P/E Multiple|Price to Earnings Multiple TNXP|Price to Earnings Ratio China SXT Pharmaceuticals, Inc.|EPRX: Company Value to Net Income|P/E Multiple BHST|EXOZ - Market Cap to Earnings|P/E Multiple ORMP (oramed.com)|P/E Multiple enterabio.com ENTX|HYFT - Price to Earnings Ratio|Business Payback Period ABVC BioPharma, Inc ABVC|CPIX: P/E Multiple|Quantum BioPharma Ltd - Company Value to Net Income|Price to Earnings Ratio FGEN|Telomir Pharmaceuticals, Inc. - Market Cap to Net Income|P/E Multiple RANI|SNYR (Synergy CHC) - Company Value to Net Income|Price to Earnings Ratio Rallybio RLYB|Lexaria Bioscience (LEXX) - Market Cap to Earnings|PULM - Price to Earnings Ratio|Business Payback Period Pheton Holdings PTHL|APM (Aptorum) - Price to Earnings Ratio|Lyra Therapeutics, Inc. (LYRA) - P/E Multiple|IBO (impactbiomedinc.com) - P/E Multiple|TNFA (TNF Pharmaceuticals) - Market Price to Net Income Ratio|Price to Earnings Ratio cbdmd.com (YCBD)|Business Payback Period PainReform Ltd|P/E Multiple CYTO (Altamira Therapeutics Ltd.)|Lipella Pharmaceuticals (LIPO) - Market Cap to Earnings|OPTN - Price to Earnings Ratio|Pieris Pharmaceuticals - Market Price to Net Income Ratio|PROC (Procaps Group) - Price to Earnings Ratio|PTPI - Business Payback Period|Price to Earnings Ratio Qilian International Holding Group Limited|SLRN: Company Value to Net Income|Price to Earnings Ratio TFFP (TFF Pharma)